Cancers, Vol. 14, Pages 694: From Interferon to Checkpoint Inhibition Therapy & mdash;A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette & ndash;Gu & eacute;rin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
Conclusion: CPIs and other IM agents now offer an increasing opportunity for bladder-preserving strategies. Studies on different substances are ongoing and will yield new findings.
Source: Cancers - Category: Cancer & Oncology Authors: Susanne Deininger Peter T örzsök Michael Mitterberger Maximilian Pallauf David Oswald Christian Deininger Lukas Lusuardi Tags: Systematic Review Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Politics | Study | Vaccines